134 related articles for article (PubMed ID: 38262199)
1. The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters.
Kumari N; Sharma R; Ali J; Chandra G; Singh S; Krishnan MY
Tuberculosis (Edinb); 2024 Mar; 145():102479. PubMed ID: 38262199
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
3. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
Front Immunol; 2020; 11():680. PubMed ID: 32411131
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate eliminates differentially culturable
Glenn SM; Turapov O; Makarov V; Kell DB; Mukamolova GV
Front Cell Infect Microbiol; 2022; 12():957287. PubMed ID: 36093181
[TBL] [Abstract][Full Text] [Related]
6. Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.
Chen C; Wicha SG; de Knegt GJ; Ortega F; Alameda L; Sousa V; de Steenwinkel JEM; Simonsson USH
CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):787-797. PubMed ID: 28657202
[TBL] [Abstract][Full Text] [Related]
7. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
[TBL] [Abstract][Full Text] [Related]
8. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Mashele SA; Steel HC; Matjokotja MT; Rasehlo SSM; Anderson R; Cholo MC
J Glob Antimicrob Resist; 2022 Jun; 29():343-352. PubMed ID: 35339735
[TBL] [Abstract][Full Text] [Related]
10. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure.
Hu Y; Pertinez H; Liu Y; Davies G; Coates A
J Antimicrob Chemother; 2019 Jun; 74(6):1627-1633. PubMed ID: 30789209
[TBL] [Abstract][Full Text] [Related]
11. The past, present and future of tuberculosis treatment.
Bi K; Cao D; Ding C; Lu S; Lu H; Zhang G; Zhang W; Li L; Xu K; Li L; Zhang Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):657-668. PubMed ID: 36915970
[TBL] [Abstract][Full Text] [Related]
12. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
13. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
[TBL] [Abstract][Full Text] [Related]
14. Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular
Sarkar S; Dyett B; Lakic B; Ball AS; Yeo LY; White JF; Soni S; Drummond CJ; Conn CE
ACS Appl Mater Interfaces; 2023 May; 15(18):21819-21829. PubMed ID: 37018059
[No Abstract] [Full Text] [Related]
15. Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia.
Mesfin EA; Merker M; Beyene D; Tesfaye A; Shuaib YA; Addise D; Tessema B; Niemann S
PLoS One; 2022; 17(8):e0271508. PubMed ID: 35930613
[TBL] [Abstract][Full Text] [Related]
16. In vitro potency of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione against drug-resistant and non-replicating persisters of Mycobacterium tuberculosis.
Rather MA; Bhat ZS; Lone AM; Maqbool M; Bhat BA; Ahmad Z
J Glob Antimicrob Resist; 2021 Jun; 25():202-208. PubMed ID: 33789204
[TBL] [Abstract][Full Text] [Related]
17. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
18. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid and Rifapentine Treatment Eradicates Persistent
Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
[No Abstract] [Full Text] [Related]
20. Drug Resistance of Mouse Somatic Cells to Rifampicin in Experimental Tuberculosis.
Nikonenko BV; Bocharova IV; Lepekha LN
Bull Exp Biol Med; 2021 May; 171(1):53-55. PubMed ID: 34050415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
